Zoetis Inc. $ZTS Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

Key Points

• Sumitomo Mitsui DS Asset Management cut its stake in Zoetis by 46.7% in Q4, selling 53,049 shares and leaving 60,572 shares valued at about $7.62 million.
• Zoetis missed Q1 (EPS $1.53 vs. ~$1.60 consensus) and set FY‑2026 guidance to $6.85–7.00 EPS, which spurred a roughly 21.8% drop in the stock and left analyst sentiment mixed (consensus "Hold", target ~$151.75).

Sumitomo Mitsui DS Asset Management Company Ltd reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 46.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,572 shares of the company's stock after selling 53,049 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Zoetis were worth $7,621,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. CIBC Asset Management Inc raised its holdings in Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company's stock worth $36,745,000 after purchasing an additional 10,434 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd boosted its holdings in shares of Zoetis by 361.2% in the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company's stock valued at $41,957,000 after buying an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company's stock valued at $205,290,000 after buying an additional 935,432 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its position in shares of Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company's stock valued at $43,235,000 after buying an additional 18,040 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group reduced their price target on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research report on Friday, February 13th. Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Citigroup started coverage on Zoetis in a research report on Wednesday, April 15th. They issued a "buy" rating and a $145.00 target price for the company. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zoetis has a consensus rating of "Hold" and a consensus target price of $151.75.

Zoetis Stock Down 21.8%

ZTS opened at $86.99 on Friday. Zoetis Inc. has a 52 week low of $85.31 and a 52 week high of $172.23. The business has a 50 day moving average price of $118.49 and a two-hundred day moving average price of $123.70. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a market cap of $36.59 billion, a PE ratio of 14.45, a P/E/G ratio of 1.71 and a beta of 0.87.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 7.01 EPS for the current year.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Livestock and international businesses provided some offset to the U.S. pet weakness, helping limit total company downside and preserving revenue diversification. Quiver Quant: Opinions on Q1
• Positive Sentiment: Some analysts and investors view the sell‑off as an overreaction given Zoetis’s scale, long‑term pet‑humanization trends and its pipeline — creating potential dip‑buy interest from institutions. Quiver Quant: Opinions on Q1
• Neutral Sentiment: Zoetis revised FY‑2026 guidance to EPS $6.85–7.00 and revenue $9.7–10.0B (vs. consensus EPS ~7.03), giving investors updated targets to model into valuations. Zoetis Press Release (PDF)
• Negative Sentiment: Q1 EPS missed expectations ($1.53 vs. $1.61 consensus) and revenue came in light (~$2.26B vs. ~$2.30B est.), triggering the initial sell reaction. Zacks: Q1 miss
• Negative Sentiment: Management cited weaker U.S. companion‑animal demand, price sensitivity among pet owners and lower veterinary visits as the primary drivers of the slowdown — factors that could persist near term and pressure the core domestic business. Benzinga: Weak pet care demand
• Negative Sentiment: Competitive pressure from generics hit legacy products (e.g., Convenia, Cerenia) and strained dermatology/parasiticide growth, raising concerns about near‑term revenue sustainability. Quiver Quant: Competitive pressures
• Negative Sentiment: Market reaction was amplified by heavy trading and negative headlines; coverage and social discussion highlighted the abrupt slowdown and the guidance cut as reasons for a sharp drop in the share price. Fool: Why shares plummeted

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.